IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2025 10-K Annual Report
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
IOVANCE BIOTHERAPEUTICS, INC. FY2025 10-K Analysis
Business Overview
- • Core business: Commercial-stage biopharma pioneering individualized tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers
- • New/regulatory: Amtagvi approved in U.S. and Canada, pending UK/Australia 2026 approvals, withdrawn and resubmitting EU MAA in 2026
Management Discussion & Analysis
- • Revenue $263.5M, up 61% YoY; Amtagvi $220.0M (up $116.5M), Proleukin $43.5M (down $17.0M)
- • Cost of sales $173.2M, up 86%; R&D $300.3M, up 9%; SG&A flat at $152.3M; total expenses $666.9M, up 19%
Risk Factors
- • Cybersecurity risk from internal systems and CROs, requiring increased resources to counter sophisticated threats
- • Dependency on IT infrastructure vulnerable to security breaches impacting business operations
IOVANCE BIOTHERAPEUTICS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$264M
▲ +60.6% YoY
Net Income
-$391M
▼ -5.1% YoY
Operating Margin
-153.1%
▲ +8785bp YoY
Net Margin
-148.4%
▲ +7846bp YoY
ROE
-56.0%
▼ -358bp YoY
Total Assets
$913M
▲ +0.3% YoY
EPS (Diluted)
$-1.09
▲ +14.8% YoY
Operating Cash Flow
-$302M
▲ +14.3% YoY
Source: XBRL data from IOVANCE BIOTHERAPEUTICS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on IOVANCE BIOTHERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.